# Bristol-Myers Squibb Company  Share Price Target ‘$61.34’, now 6.0% Upside Potential

- Link: https://www.directorstalkinterviews.com/bristol-myers-squibb-company-share-price-target-61-34-now-6-0-upside-potential/4121187584
- Published: 2025-02-25T14:40:23+00:00
- Author: Charlotte Edwards

**Bristol-Myers Squibb Company** which can be found using ticker (BMY) have now 
21 market analysts covering the stock. The analyst consensus now points to a rating
of ‘hold’. The target price High/Low ranges between $70.00 and $37.00 suggesting
an average analyst share price target price of $61.34. (at the time of writing).
Given that the stocks previous close was at $57.88 and the analysts are correct 
then there would likely be a percentage uptick in value of 6.0%. The day 50 moving
average is $57.06 and the 200 day moving average is $50.71. The market cap for the
company is 120.95B. Currently the stock stands at: $59.60 USD

 The potential market cap would be $128,174,948,123 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $23.83 and
a 6.55% return on assets.

Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged
in the discovery, development, licensing, manufacturing, marketing, distribution,
and sale of biopharmaceutical products. It offers products for a range of therapeutic
classes, which include oncology, immunology, cardiovascular and hematology. Its 
pharmaceutical products include chemically synthesized or small molecule drugs and
products produced from biological processes, called biologics. Biologics are administered
to patients through injections or by infusion. Its products include Revlimid, Abecma,
Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti,
Reblozyl, Inrebic, Onureg, Zeposia, Camzyos, and Breyanzi. It also has a pipeline
of investigational medicines designed to target the common mutations associated 
with oncogenesis, including repotrectinib. Its products are sold to wholesalers,
distributors, pharmacies, retailers, hospitals, clinics, and government agencies.

Share on:
